Sutter Health leads groundbreaking clinical studies including those described below.
- TAPUR™ study will help improve treatment for patients with advanced cancers — Sutter Health is enrolling patients to the Targeted Agent and Profiling Utilization (TAPUR™) study, a national, prospective, non-randomized clinical trial determining the safety and efficacy of approved, targeted anticancer drugs. “The study enrolls patients with advanced cancer who are not responding to standard treatment and who have genomic alterations in their tumors that can be targeted with a TAPUR™ study drug,” says Stacy D’Andre, MD, Executive Chair of the Sutter Cancer Research Consortium, Medical Director at Sutter Cancer Center, and Principle Investigator for the study at Sutter. “By offering this study through the Sutter Cancer Research Consortium, we are providing our patients with novel therapies that they would otherwise not have access to.” Learn more about the TAPUR™ study at Sutter Health.
- STRIVE: Sutter’s largest-enrolling clinical trial to date — Sutter Health sites across Northern California, the Mayo Clinic, and other institutions participated in STRIVE, a study that enrolled over 38,000 Sutter patients at 11 mammography centers in under 20 months. Begun in 2017 and now closed to enrollment, the study is evaluating a new tool for the detection of early-stage breast cancer. The test is being developed by GRAIL, Inc., a healthcare company based in Menlo Park. “Given its location in Northern California, one of the most diverse populations worldwide, Sutter Health research work with the STRIVE study could help pioneer breakthroughs in early diagnosis that may help improve patients’ experiences throughout the United States and beyond,” says Michael Rowbotham, MD, Chief Research Officer and VP, Sutter Health/ Scientific Director. See how STRIVE is helping improve breast cancer detection at Sutter Health.
- Sutter Health one of the top U.S. sites enrolling patients to the PARTNER 3 study of TAVR in low-risk patients — Transcatheter aortic valve replacement (TAVR) is a minimally invasive procedure done without open-heart surgery to replace a narrowed aortic valve. The procedure is one of several research breakthroughs and interventional cardiology advances being pioneered at Sutter Health through the research of David Daniels, MD, an interventional cardiologist at Mills-Peninsula Medical Center and CPMC, and collaborators across Sutter. Results from the PARTNER 3 clinical trial were published March 16 in the NEJM with Sutter Health investigators as co-authors. Find out how research is helping lead Sutter Health to a new era in cardiology care.